文献速递银屑病与炎症性皮肤病皮肤肿瘤

古塞奇尤单抗治疗中重度银屑病5年随访恶性肿瘤发生率:VOYAGE 1和VOYAGE 2汇总结果

Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.
PubMed 文献 · J Am Acad Dermatol · 2023-04-03

汇总VOYAGE 1和VOYAGE 2两项试验中1721例接受古塞奇尤单抗治疗的中重度银屑病患者,随访长达5年。结果显示恶性肿瘤(除外非黑色素瘤皮肤癌)发生率为0.45/100患者年,与银屑病纵向评估登记处报告的0.68/100患者年及美国一般人群预期发生率(标准化发病比=0.93)基本一致。

要点

  • 古塞奇尤单抗治疗随访超7100患者年,非黑色素瘤皮肤癌发生率为0.34/100患者年。
  • 除外非黑色素瘤皮肤癌的恶性肿瘤发生率为0.45/100患者年。
  • 标准化发病比=0.93,与美国一般人群预期发生率基本一致。

核心结论

  • 古塞奇尤单抗治疗长达5年的患者中,恶性肿瘤发生率低,且与一般人群及银屑病患者人群中的发生率总体一致。

研究设计与样本

  • 汇总VOYAGE 1和VOYAGE 2两项试验中1721例接受古塞奇尤单抗治疗的中重度银屑病患者,评估每100患者年的累积恶性肿瘤发生率。
  • 将除外非黑色素瘤皮肤癌的恶性肿瘤发生率与银屑病纵向评估和登记处的发生率进行比较。
  • 计算标准化发病比,比较古塞奇尤单抗治疗患者(除外非黑色素瘤皮肤癌和原位宫颈癌)与美国一般人群(基于监测、流行病学和最终结果数据)的恶性肿瘤发生率,并校正年龄、性别和种族。

主要发现

  • 1721例接受古塞奇尤单抗治疗的患者累计超过7100患者年,其中24例发生非黑色素瘤皮肤癌(0.34/100患者年;基底细胞癌与鳞状细胞癌比例为2.2:1),32例发生除外非黑色素瘤皮肤癌的恶性肿瘤(0.45/100患者年)。
  • 银屑病纵向评估和登记处中除外非黑色素瘤皮肤癌的恶性肿瘤发生率为0.68/100患者年。
  • 古塞奇尤单抗治疗患者中除外非黑色素瘤皮肤癌和原位宫颈癌的恶性肿瘤发生率与美国一般人群预期发生率一致(标准化发病比=0.93)。

局限性

  • 原文指出,恶性肿瘤发生率的确定存在固有的不精确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malignancy risk surveillance among patients receiving long-term immunomodulatory psoriasis treatments remains an important safety objective. OBJECTIVE: To report malignancy rates in patients with moderate-to-severe psoriasis treated with guselkumab for up to 5 years versus general and psoriasis patient populations. METHODS: Cumulative rates of malignancies/100 patient-years (PY) were evaluated in 1721 guselkumab-treated patients from VOYAGE 1 and 2. Malignancy rates (excluding nonmelanoma skin cancer [NMSC]) were compared with rates in the Psoriasis Longitudinal Assessment and Registry. Standardized incidence ratios comparing malignancy rates (excluding NMSC and cervical cancer in situ) between guselkumab-treated patients and the general US population using Surveillance, Epidemiology, and End Results data were calculated, adjusting for age, sex, and race. RESULTS: Of 1721 guselkumab-treated patients (>7100 PY), 24 had NMSC (0.34/100PY; basal:squamous cell carcinoma ratio, 2.2:1), and 32 had malignancies excluding NMSC (0.45/100PY). For comparison, the malignancy rate excluding NMSC was 0.68/100PY in the Psoriasis Longitudinal Assessment and Registry. Malignancy rates (excluding NMSC/cervical cancer in situ) in guselkumab-treated patients were consistent with those expected in the general US population (standardized incidence ratio = 0.93). LIMITATIONS: Inherent imprecision in determining malignancy rates. CONCLUSIONS: In patients treated with guselkumab for up to 5 years, malignancy rates were low and generally consistent with rates in general and psoriasis patient populations.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Lebwohl M, Langley RG, et al. Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2023. PMID: 37019386. doi:10.1016/j.jaad.2023.03.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。